Drug Search Results
More Filters [+]

Balstilimab

Alternative Names: balstilimab, agen-2034, agen2034, agen 2034
Latest Update: 2024-07-11
Latest Update Note: Clinical Trial Update

Product Description

AGEN2034 is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 from interacting with its ligands PD-L1 and PD-L2. (Sourced from: https://agenusbio.com/agen2034-anti-pd-1/)

Mechanisms of Action: PD-1 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation:
Fast Track - Cervical Cancer
Fast Track - Colorectal Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Agenus
Company Location: LEXINGTON MA 02421
Company CEO: Garo H. Armen
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Balstilimab

Countries in Clinic: Armenia, Australia, Belgium, Brazil, Chile, China, Estonia, France, Georgia, Hungary, Italy, Korea, Mexico, Moldova, Netherlands, Peru, Poland, Russia, Spain, Taiwan, Thailand, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 25

Highest Development Phases

Phase 3: Adenocarcinoma|Colorectal Cancer|Gastrointestinal Cancer|Oncology Solid Tumor Unspecified

Phase 2: Bladder Cancer|Brain Cancer|Cervical Cancer|Glioblastoma|Gliosarcoma|Kidney Cancer|Liver Cancer|Lymphoma|Melanoma|Non-Small-Cell Lung Cancer|Oropharyngeal Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Prostate Cancer|Renal Cell Carcinoma|Uterine Cancer

Phase 1: Endometrial Cancer|Hemangiosarcoma|Ovarian Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

IMMONC0008

P2

Recruiting

Non-Small-Cell Lung Cancer

2030-04-01

IMMONC0001

P2

Recruiting

Lymphoma

2029-09-01

NEOASIS

P3

Recruiting

Oncology Solid Tumor Unspecified

2029-01-29

BBOpCo

P2

Not yet recruiting

Colorectal Cancer

2028-07-01

Recent News Events